SuperworthSerina Therapeutics SER
- Market cap
- $41.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −50.6%
Serina Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $29K+222% | $3.1M+38488% | $5K−83% | $51K+629% | $14K−52% | n/a | $0 | $130K+155% | $0 | n/a | n/a | $0 | |
| Cost of revenue | $33K+560% | $1K+0% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | $34K+750% | $55K+686% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $603K+272% | $907K+336% | $1.1M+177% | $1.6M+233% | $2.4M+301% | n/a | $3M+167% | $3.2M+98% | $3.7M+51% | n/a | $3.2M+8% | $3.8M+21% |
| SG&A | $889K−36% | $1.9M+23% | $1.2M+106% | $2.3M+391% | $2.9M+227% | n/a | $2.9M+138% | $2.5M+10% | $2.7M−6% | n/a | $3.1M+6% | $3M+17% |
| −$1.5M−6% | $241K | −$2.3M+141% | −$3.9M+309% | −$5.3M+263% | n/a | −$5.9M+152% | −$5.6M+44% | −$6.4M+20% | n/a | n/a | −$6.8M+22% | |
| Interest expense | $100K−89% | $176K−82% | $186K+116% | $307K+184% | $16K−84% | n/a | $0 | $9K−97% | $6K−63% | n/a | $189K | $203K+2156% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | −$4.8M | n/a | n/a | n/a | −$6.9M+43% | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $7K | n/a | |
| Net income | $1.8M | $1.1M | −$15M | $5.2M+544% | $1.4M−20% | −$2.7M | −$4.8M−68% | −$6.4M | −$4.6M | −$3.3M+22% | −$6.9M+43% | −$6.4M−1% |
| $0.23 | −$3.20+28% | −$5.38 | $0.51+364% | $0.13−44% | −$0.30−91% | −$0.49−91% | −$0.66 | −$0.45 | −$0.32+7% | −$0.58+18% | −$0.55−17% | |
| 7.6M−80% | 1.1M−0% | 2.8M−67% | 10.2M+37% | 10.8M+42% | 9.1M+744% | 9.8M+250% | 10M−2% | 10.3M−4% | 10.7M+17% | 12M+24% | 16.4M+64% |
EPS, diluted: 11 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x35.17). Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x35.17).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Serina Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SERSerina Therapeutics | $41.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $69M | 11.1× | 14.5× | 0.4× | −3% | 3.7% |
More on Serina Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .